Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Mariana Amélia MonteiroUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-6015-9924
Carlos Fernando ApolianoUniversidade de São Paulo, Faculdade de Medicina, Departamento de Dermatologia, Laboratório de Imunodeficiências Secundárias (LIM-56), São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-3963-7661
José Eduardo Rodrigues MartinsUniversidade de São Paulo, Faculdade de Medicina, Departamento de Dermatologia, Laboratório de Imunodeficiências Secundárias (LIM-56), São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0009-0001-4763-6351
Noemia Orii SunadaUniversidade de São Paulo, Faculdade de Medicina, Departamento de Dermatologia, Laboratório de Imunodeficiências Secundárias (LIM-56), São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-4019-5925
Víctor Ângelo FolgosiUniversidade de São Paulo, Faculdade de Medicina, Departamento de Dermatologia, Laboratório de Imunodeficiências Secundárias (LIM-56), São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-0114-7587
Najara Ataíde de Lima NascimentoUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-1876-5955
Ana Paula Rocha VeigaUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-8816-6878
Luisa de Oliveira PereiraUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-0725-4594
Luisa Caracik de Camargo AndradeUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0009-0001-8288-4051
Larissa TibertoUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-5468-3746
Maurício Domingues FerreiraUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-9068-2188
Luiz Augusto Marcondes FonsecaUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-3113-8558
Alberto José da Silva DuarteUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-8707-4904
Denise Arakaki-SanchezMinistério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis, Brasília, Distrito Federal, Brazil.ORCID http://orcid.org/0000-0001-8026-2876
Jorge CassebUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Dermatologia, Ambulatório de Imunodeficiências Secundárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-4553-2559
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Tuberculosis (TB) is the most common comorbidity in people living with HIV/AIDS (PLWH), including those under antiretroviral treatment. PLWH are 28 times more likely to develop TB in Brazil, the leading cause of HIV-related deaths globally, with approximately 161,000 reported deaths worldwide in 2023. Early diagnosis of latent tuberculosis infection (LTBI) and prophylactic therapy can reduce TB cases, prevent disease progression, and decrease transmission in high-risk populations. This study assessed the prevalence of LTBI in PLWH using the interferon-gamma release assay (IGRA) and the impact of the 3HP regimen (isoniazid [INH]/rifapentine [RPT]) as prophylactic treatment. Blood samples from 335 PLWH (78% of the 427 in the cohort) were tested for IGRA; 50 PLWH (15%) tested positive and were treated with 3HP. Treatment included 900 mg of INH and 900 mg of RPT in 12 weekly doses according to the Brazilian health guidelines. No specific risk factors, including nadir CD4+T count, age, gender, or antiretroviral therapy (ART), were more frequently observed in the PLWH with LTBI compared to the PLWH without LTBI. All PLWH with LTBI received treatment and no cases of active TB were observed. Our findings highlight the need for wider LTBI screening and treatment among PLWH in the latent phase, emphasizing more stringent approaches for implementing 3HP prophylaxis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Eradicating latent tuberculosis: use of interferon gamma release assay and isoniazid/rifapentine in people living with HIV/AIDS. · full record | OpenQuestion